Menaquinone-7 (Vitamin K2-7)
(Synonyms: 维生素K2(35),Vitamin K2-7; Vitamin K2(35); Vitamin MK-7) 目录号 : GC32498
Menaquinone-7 (Vitamin K2-7)是维生素K系列中非常有价值的一员，除了对凝血有积极作用外，还对预防骨质疏松症和心血管疾病有显著作用。
Cas No.:2124-57-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Menaquinone-7 (Vitamin K2-7), a highly valuable member of the vitamin K series, has significant effects on preventing osteoporosis and cardiovascular disease besides its positive effects on blood coagulation [1].
Menaquinone-7 (10 µM) treated MC3T3E1 cells for 24, 48, 96 and 240 h, no statistical differences at 24, 48 and 96 h, the growth of MK-7 treated cells was significantly suppressed at 240 h. Menaquinone-7 increased osteocalcin, osteoprotegerin, and RANKL mRNA expression in osteoblastic MC3T3E cells [2]. After 24 h of Menaquinone-7 administration, genes upregulated by Menaquinone-7 included tenascin C and BMP2. Genes downregulated by Menaquinone-7 administration included biglycan and butyrophilin [3]. Menaquinone-7 (1 µM) increases alkaline phosphatase activity and calcium content in femoral-metaphyseal tissues isolated from normal and skeletal-unloaded rats [4]. Menaquinone-7 (10 µM) promotes osteoblast maturation thereby increasing osteogenic differentiation [5].
Menaquinone-7 increased The bone formation marker osteocalcin (OC), which is the bone formation marker [6]. Menaquinone-7 (200 mg/1,000 g fed with diets) supplementation decreases the bone resorption index and increases the bone formation index, balancing bone metabolism, and is considered to prevent bone loss [6].
References:
[1]. Mahdinia E, Demirci A, Berenjian A. Production and application of menaquinone-7 (vitamin K2): a new perspective[J]. World Journal of Microbiology and Biotechnology, 2017, 33(1): 1-7.
[2]. Katsuyama H, Otsuki T, Tomita M, et al. Menaquinone-7 regulates the expressions of osteocalcin, OPG, RANKL and RANK in osteoblastic MC3T3E1 cells[J]. International journal of molecular medicine, 2005, 15(2): 231-236.
[3]. Katsuyama H, Saijoh K, Otsuki T, et al. Menaquinone-7 regulates gene expression in osteoblastic MC3T3E1 cells[J]. International journal of molecular medicine, 2007, 19(2): 279-284.
[4]. Ehara Y, Takahashi H, Hanahisa Y, et al. Effect of vitamin K2 (menaquinone-7) on bone metabolism in the femoral-metaphyseal tissues of normal and skeletal-unloaded rats: enhancement with zinc[J]. Research in experimental medicine, 1996, 196(1): 171-178.
[5]. Akbulut A C, Wasilewski G B, Rapp N, et al. Menaquinone-7 supplementation improves osteogenesis in pluripotent stem cell derived mesenchymal stem cells[J]. Frontiers in cell and developmental biology, 2021, 8: 618760.
[6]. Brown J P, Malaval L, Chapuy M C, et al. Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis[J]. The Lancet, 1984, 323(8386): 1091-1093.
| Cell experiment [1]: | |
|
Cell lines |
Primary astrocytes |
|
Preparation Method |
The astrocytes were divided into the pretreatment group and no pretreatment group. In the pretreatment group, the astrocytes were pretreated for 30 h with Menaquinone-7 concentrations (10, 50, 100, and 150 µM) with 10% FBS in DMEM/F12. They were then maintained under either normoxic (5% CO2 /95% air, 37°C) or hypoxic (5% CO2 /95% N2, 37°C) conditions for different time intervals. The culture medium was changed to glucose-free Dulbecco's Modified Eagle's Medium without FBS before incubating the astrocytes under hypoxic onditions. Hypoxia was induced by incubating the astrocytes using the hypoxic workstation. |
|
Reaction Conditions |
10, 50, 100, and 150 µM for 30 h |
|
Applications |
Pretreatment with Menaquinone-7 did not cause these apparent morphological alterations in these astrocytes. the morphological alterations in astrocytes pretreated with Menaquinone-7 were reduced and the number of adherent astrocytes significantly increased under hypoxic conditions. |
| Animal experiment [2]: | |
|
Animal models |
4-week-old C57BL/6J male mice |
|
Preparation Method |
The AIN-93G diets consisted of a normal diet (N), normal diet + vitamin K1 (N-K1), normal diet + Menaquinone-7 (N-K2), 45% high-fat diet (HF), 45% high-fat diet + vitamin K1 (HF-K1), and a 45% high-fat diet + Menaquinone-7 (HF-K2). The vitamin K1 and Menaquinone-7 contents were 200 mg/1,000 g, and the diet was provided in pellet form. Food intake amount was measured every other day. Body weight was measured once a week, and the food efficiency ratio (FER) was calculated by dividing the increased body weight from day1 to the final day by the food intake amount during the experiment period. |
|
Dosage form |
200 mg/1,000 g fed with AIN-93G diets |
|
Applications |
Osteocalcin (OC) level of HF groups which were supplemented with vitamin K1 or Menaquinone-7, was higher than that in the HF diet-only group , type I collagen Ctelopeptide (CTx) was lower in the vitamin K-supplemented HF groups than the HF diet-only group. |
|
References: [1]: Yang R Y, Pan J Y, Chen Y, et al. Menaquinone-7 protects astrocytes by regulating mitochondrial function and inflammatory response under hypoxic conditions[J]. Eur. Rev. Med. Pharmacol. Sci, 2020, 24: 10181-10193. | |
| Cas No. | 2124-57-4 | SDF | |
| 别名 | 维生素K2(35),Vitamin K2-7; Vitamin K2(35); Vitamin MK-7 | ||
| Canonical SMILES | O=C1C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)\C)=C(C)C(C2=C1C=CC=C2)=O | ||
| 分子式 | C46H64O2 | 分子量 | 649 |
| 溶解度 | DMSO : 5 mg/mL (7.70 mM);Water : < 0.1 mg/mL (insoluble) | 储存条件 | Store at -20°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.5408 mL | 7.7042 mL | 15.4083 mL |
| 5 mM | 0.3082 mL | 1.5408 mL | 3.0817 mL |
| 10 mM | 0.1541 mL | 0.7704 mL | 1.5408 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet